ABL Diagnostics wins court approval to take over TEXCELL activities

ABL Diagnostics has been designated by the Évry commercial court to acquire TEXCELL’s assets and operations, keeping the Genopole site in Évry-Courcouronnes open and transferring 29 employees. The deal expands ABL Diagnostics’ footprint in virology, biosafety and molecular diagnostics while supporting its broader life sciences strategy.

Why it matters: - The takeover gives ABL Diagnostics a stronger position in virology, biosafety and infectious-disease services. - The deal preserves scientific expertise and keeps operations at the Genopole d'Évry-Courcouronnes site. - The acquisition adds complementary capabilities that can support ABL Diagnostics’ molecular diagnostics and research pipeline.

What happened: - ABL Diagnostics was designated by the Tribunal de commerce d'Évry to take over TEXCELL’s assets and activities. - The decision follows ABL Diagnostics’ industrial plan to maintain operations and develop synergies with its existing businesses. - The transaction is tied to a court-led transfer process and remains subject to required legal and administrative formalities.

The details: - The takeover covers TEXCELL’s strategic assets and activities. - Commercial contracts transferred in the deal will continue. - Operations will stay at the Genopole d'Évry-Courcouronnes site. - ABL Diagnostics will take on 29 employees, including 23 permanent staff and 6 trainees. - The company will assume acquired employee rights for 91,829.24 euros, subject to adjustment. - TEXCELL traces its origins to the scientific ecosystem of Institut Pasteur. - TEXCELL has expertise in viral safety, biosafety, genomic analysis, immune monitoring and services for biotechnology and innovative therapies. - Publicly available data show TEXCELL France posted about 5.4 million euros in revenue in 2024, after 6.2 million euros in 2023 and 7.5 million euros in 2022. - The project’s total economic value is about 2.9 million euros. - That figure includes a 225,000-euro asset sale price, split between 165,000 euros for intangible assets and 60,000 euros for tangible assets. - The deal also includes a 30,000-euro purchase of inventory. - ABL Diagnostics will reconstitute security deposits for about 100,000 euros. - The company will take over equipment-related leasing contracts and upcoming installments worth 531,792.74 euros, subject to adjustment. - A planned industrial and technology investment is estimated at 930,000 euros. - Working capital needs are estimated at 1 million euros to support the acquired operations. - ABL Diagnostics said the transaction is financed with the Group’s available financial resources. - The terms of the winning bid are in documents filed with the Tribunal de commerce d'Évry. - TEXCELL’s capabilities in viral safety, biological control, cell culture, viral characterization and biosafety complement ABL Diagnostics’ UltraGene, DeepChek® and Nadis® platforms. - ABL Diagnostics expects to recruit about five additional employees to support the site. - The company plans to continue developing the scientific value of the acquired assets, including characterized virus banks, cell line collections and biosafety infrastructure. - Those resources are intended to support future tools for biomedical research, biological quality control and molecular diagnostics.

Between the lines: - The deal fits ABL Diagnostics’ broader push toward life sciences and infectious-disease markets. - The link to Institut Pasteur matters because both companies share scientific roots and overlapping research focus areas. - The acquisition looks designed to combine revenue-generating services with assets that may feed future R&D. - The court process and stated risks mean integration timing and execution remain uncertain.

What's next: - ABL Diagnostics will later disclose how TEXCELL’s activities will be integrated. - The company also plans to update the market on how the acquisition fits its 2026 strategic roadmap and targets. - Management said it intends to invest in automation, infrastructure upgrades, team expansion and scientific development to support international customers. - Additional hiring and site integration are expected as the business is absorbed into ABL Diagnostics.